keyword
MENU ▼
Read by QxMD icon Read
search

oral agents diabetes

keyword
https://www.readbyqxmd.com/read/28437809/reactive-rather-than-proactive-diabetes-management-in-the-perioperative-period
#1
Inge Hommel, Petra J van Gurp, Alfons A den Broeder, Hub Wollersheim, Femke Atsma, Marlies E J L Hulscher, Cees J Tack
As perioperative hyperglycemia is associated with poor postoperative patient outcomes, clinical guidelines provide recommendations for optimal perioperative glucose control. It is unclear to what extent recommended glucose levels are met in daily practice, and little is known about factors that influence these levels. We describe blood glucose levels throughout the hospital care pathway in 375 non-critically ill patients with diabetes who underwent major surgery (abdominal, cardiac, or orthopedic) in 6 hospitals, examine determinants of these levels including adherence to 9 quality indicators for optimal perioperative diabetes care, and perform qualitative interviews to identify barriers for optimal care...
April 24, 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/28431670/use-of-glp-1-receptor-agonists-for-type-2-diabetes-treatment-intensification-after-basal-insulin-failure
#2
M Joubert, Y Reznik
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are part of the armamentarium for the treatment of type 2 diabetes (T2D), although recent guidelines have mainly recommended their use on top of oral treatments when a single or combination of two or three oral hypoglycaemic agents has failed to lower HbA1c levels below the individualized target range. In such situations, the decision to use GLP-1RAs is mostly driven by their high level of efficacy, their effect on body weight balance and their safety considerations, such as low hypoglycaemic risk...
April 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28427734/comparison-of-outcomes-and-prognosis-of-patients-with-versus-without-newly-diagnosed-diabetes-mellitus-after-primary-percutaneous-coronary-intervention-for-st-elevation-myocardial-infarction-the-horizons-ami-study
#3
Konstanze Ertelt, Sorin J Brener, Roxana Mehran, Ori Ben-Yehuda, Thomas McAndrew, Gregg W Stone
A history of diabetes mellitus (DM) is an independent predictor for adverse events in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. Outcomes of patients with STEMI and newly diagnosed DM (NDM) are less well described. We used the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial database to identify the outcomes at 30 days and 3 years according to no, known, and NDM in patients with STEMI...
March 29, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28423281/moringa-olifera-leaves-aqueous-extract-ameliorates-hepatotoxicity-in-alloxan-induced-diabetic-rats
#4
Mabrouk Attia Abd Eldaim, Ahmed Shaban, Samy Abd Elaziz
This study was carried out to evaluate the possible mechanisms through which the Moringa oleifera leaves aqueous extract reveals its hepatoprotective effects in alloxan induced diabetic rats. Eighty albino rats were assigned into four groups. The control group was given sterile saline. The second group was injected with alloxan (150 mg/kg BW) i.p. The third group was given Moringa oleifera leaves aqueous extract (250 mg/kg BW) orally daily. The fourth group was injected with alloxan as the second group and administrated Moringa oleifera leaves aqueous extract as in the third group...
April 19, 2017: Biochemistry and Cell Biology, Biochimie et Biologie Cellulaire
https://www.readbyqxmd.com/read/28420696/erratum-benefits-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-versus-insulin-glargine-and-lixisenatide-monocomponents-in-type-2-diabetes-inadequately-controlled-on-oral-agents-the-lixilan-o-randomized-trial-diabetes
#5
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies
No abstract text is available yet for this article.
April 18, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28418203/effectiveness-of-vildagliptin-as-add-on-to-metformin-monotherapy-among-uncontrolled-type-2-diabetes-mellitus-patients-in-a-real-world-setting
#6
Cheli Melzer Cohen, Carla Davis, Varda Shalev, Gabriel Chodick
BACKGROUND: Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP4-i) commonly used as a dual oral agent with metformin, thiazolidinediones, or sulfonylurea for type 2 diabetes mellitus (T2DM). The efficacy of dual therapy with vildagliptin and metformin has been established in randomized clinical trials but little evidence exists from observational studies. The aims of the present study were to evaluate the effectiveness of vildagliptin as an add-on therapy to metformin in reducing HbA1c as well as its influences on body weight and blood lipids in a real-life setting...
April 18, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#7
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28413872/favorable-effect-on-blood-volume-control-in-hemodialysis-patients-with-type-2-diabetes-after-switching-from-insulin-therapy-to-liraglutide-a-human-glucagon-like-peptide-1-analog-results-from-a-pilot-study-in-japan
#8
Masumi Kondo, Masao Toyoda, Moritsugu Kimura, Naoto Ishida, Masafumi Fukagawa
OBJECTIVE: Hemodialysis patients are advised to limit the intake of foods in order to control volume status and body weight (BW). We report the clinical course of five Japanese hemodialysis patients with type 2 diabetes mellitus (T2DM) who were switched from insulin to liraglutide, and the efficacy of the treatment, especially in terms of changes in interdialysis weight gain (IDWG). METHODS: This retrospective pilot study included 5 Japanese hemodialysis patients with T2DM...
April 20, 2017: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/28413457/persicarin-isolated-from-oenanthe-javanica-protects-against-diabetes-induced-oxidative-stress-and-inflammation-in-the-liver-of-streptozotocin-induced-type-1-diabetic-mice
#9
Joo Young Lee, Min Yeong Kim, Sung Ho Shin, Mi-Rae Shin, O Jun Kwon, Tae Hoon Kim, Chan Hum Park, Jeong Sook Noh, Man Hee Rhee, Seong-Soo Roh
Persicarin is one of the major components of the Oenanthe javanica (water dropwort). The present study was aimed to evaluate the role of persicarin in the hepatic tissue of streptozotocin-induced type 1 diabetic mice. Diabetes was induced by single intra-peritoneal injection of streptozotocin (120 mg/kg body weight) and then oral administration of persicarin at a dose 2.5 and 5 mg/kg body weight for 10 days. Serum and hepatic glucose levels were increased in diabetic control mice, while persicarin treatment groups were markedly reduced...
April 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28411624/adverse-drug-events-observed-in-patients-with-type-2-diabetes-mellitus-treated-with-100%C3%A2-mg-versus-300%C3%A2-mg-canagliflozin-a-systematic-review-and-meta-analysis-of-published-randomized-controlled-trials
#10
Pravesh Kumar Bundhun, Girish Janoo, Feng Huang
BACKGROUND: Nowadays, canagliflozin monotherapy, or in combination with other oral hypoglycemic agents (OHAs), is often administered in patients who are treated for type 2 diabetes mellitus (T2DM). Therefore, we aimed to systematically compare the adverse drugs events (AEs) which were associated with 100 mg versus 300 mg canagliflozin respectively, using a large number of randomized patients with T2DM which were obtained from published trials. METHODS: Randomized controlled trials (RCTs) comparing 100 mg versus 300 mg canagliflozin in patients who were treated for T2DM were searched from electronic databases...
April 16, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28407662/effects-of-a-one-week-fasting-therapy-in-patients-with-type-2-diabetes-mellitus-and-metabolic-syndrome-a-randomized-controlled-explorative-study
#11
Chenying Li, Badri Sadraie, Nico Steckhan, Christian Kessler, Rainer Stange, Michael Jeitler, Andreas Michalsen
There is increasing experimental evidence for beneficial effects of calorie restriction and intermittent fasting in type 2 diabetes mellitus (T2DM). In humans, prolonged fasting is established as a health-promoting complementary treatment in Europe and claimed to improve metabolism by a complex hormetic response. We aimed to investigate effects of a one-week fasting period compared to usual care in T2DM by means of a pilot trial. Patients with manifest T2DM medically treated with oral hypoglycemic agents and/or insulin were randomly assigned to a 7-day fasting program followed by dietary advice or to usual care and dietary advice only...
April 13, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28406239/cmd-05-a-novel-promising-clinical-anti-diabetic-drug-candidate-in-vivo-and-vitro-studies
#12
Jie Ma, Huan Li, Xiangnan Hu, Lu Yang, Qi Chen, Congli Hu, Zhihao Chen, Xiaoyan Tian, Yang Yang, Ying Luo, Run Gan, Junqing Yang
Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC50 of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro. In diabetes rat model established by high fat diet/low dose streptozotocin, CMD-05 inhibited DPP-IV activity, significantly improved glucose tolerance, increased GLP-1 and insulin levels in plasma...
April 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28405576/evaluation-of-anti-diabetic-activity-of-ahpl-aytab-0513-tablet-in-streptozotocin-induced-diabetes-in-rats
#13
Sanjay U Nipanikar, Soham S Chitlange, Dheeraj Nagore
BACKGROUND: Diabetes is a chronic, progressive disease associated with several complications leading to significant mortality and morbidity. Limitations and drawbacks of the conventional treatment generate need for safer, effective complimentary therapies to prevent complications, and maintain normoglycemic status. AIM AND OBJECTIVES: The aim of this study is to to evaluate antidiabetic activity of AHPL/AYTAB/0513 tablet alone, oral hypoglycemic agents (OHA[s]), and combination of AHPL/AYTAB/0513 tablet and OHA(s) in streptozotocin-induced diabetes in rats...
January 2017: International Journal of Pharmaceutical Investigation
https://www.readbyqxmd.com/read/28405346/safety-and-efficacy-of-saxagliptin-for-glycemic-control-in-non-critically-ill-hospitalized-patients
#14
Rajesh Garg, Brooke Schuman, Shelley Hurwitz, Cheyenne Metzger, Shreya Bhandari
OBJECTIVE: To evaluate whether saxagliptin is non-inferior to basal-bolus insulin therapy for glycemic control in patients with controlled type 2 diabetes mellitus (T2DM) admitted to hospital with non-critical illnesses. RESEARCH DESIGN AND METHODS: This was an open-label, randomized controlled clinical trial. Patients received either saxagliptin or basal-bolus insulin, both with correctional insulin doses. The main study outcome was the mean daily blood glucose (BG) after the first day of randomization...
2017: BMJ Open Diabetes Research & Care
https://www.readbyqxmd.com/read/28392860/the-effect-of-tofogliflozin-treatment-on-postprandial-glucose-and-lipid-metabolism-in-japanese-men-with-type-2-diabetes-a-pilot-study
#15
Hirokazu Kakuda, Junji Kobayashi, Masaru Sakurai, Masahiro Kakuda, Noboru Takekoshi
BACKGROUND: Postprandial hyperglycemia and hyperlipidemia are highly related to the development of atherosclerosis. Sodium/glucose cotransporter-2 (SGLT2) inhibitors have attracted attention as a new class of anti-diabetic agents for the treatment of type 2 diabetes. We investigated the effect of tofogliflozin on postprandial glucose and lipid metabolism in Japanese male patients with type 2 diabetes. METHODS: Ten Japanese men with type 2 diabetes (average age 66...
May 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28392679/depressive-symptoms-and-adherence-to-cardiometabolic-therapies-across-phases-of-treatment-among-adults-with-diabetes-the-diabetes-study-of-northern-california-distance
#16
Amy M Bauer, Melissa M Parker, Howard H Moffet, Dean Schillinger, Nancy E Adler, Alyce S Adams, Julie A Schmittdiel, Wayne J Katon, Andrew J Karter
OBJECTIVE: Among adults with diabetes, depression is associated with poorer adherence to cardiometabolic medications in ongoing users; however, it is unknown whether this extends to early adherence among patients newly prescribed these medications. This study examined whether depressive symptoms among adults with diabetes newly prescribed cardiometabolic medications are associated with early and long-term nonadherence. PATIENTS AND METHODS: An observational follow-up of 4,018 adults with type 2 diabetes who completed a survey in 2006 and were newly prescribed oral antihyperglycemic, antihypertensive, or lipid-lowering agents within the following year at Kaiser Permanente Northern California was conducted...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28387494/-optimizing-basal-insulin-therapy-in-type-2-diabetes
#17
A J Scheen, N Paquot
Because of the natural history of type 2 diabetes and the increasing life expectancy, more and more patients are treated with insulin after failure of oral therapy. International guidelines give the preference to basal insulin, most often while maintaining metformin. If this treatment does not allow to reach the glycaemic objectives, optimizing therapy is mandatory. This clinical case offers the opportunity of discussing both advantages and disadvantages of three therapeutic options : the shift from basal insulin to a basal-plus or a basal-bolus insulin regimen, the addition of another oral glucose-lowering agent, either a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of cotransporters sodium-glucose type 2 cotransporters (gliflozin), or the combination of basal insulin and a glucagon-like peptide-1 receptor agonist...
March 2017: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28387100/-about-the-choice-between-a-dpp-4-inhibitor-and-a-sglt-2-inhibitor-tor-treating-type-2-diabetes
#18
REVIEW
A J Scheen, N Paquot
Two new classes of oral antidiabetic agents play an increasing role in the management of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and sodiumglucose cotransporters type 2 (SGLT2) inhibitors (gliflozins). After failure of a monotherapy with metformin (first pharmacological choice in type 2 diabetes), both may offer an alternative to the add-on of a sulphonylurea, especially in patients at risk of hypoglycaemia. However, the choice between a DPP-4 inhibitor and a SGLT2 inhibitor is not easy and should be oriented based upon the individual patient characteristics...
December 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28383856/-dapagliflozin-forxiga%C3%A2-sglt-2-cotransporter-inhibitor-as-glucose-lowering-agent-in-type-2-diabetes
#19
REVIEW
A J Scheen
Dapagliflozin, a specific inhibitor of sodium-glu¬cose cotransporters type 2 (SGLT2, inhibits glucose reabsorp¬tion in renal tubules and thus promotes glucosuria. This effect results in a reduction in fasting and postprandial glycaemia and a decrease of glycated haemoglobin (HbA1c), with a minor risk of hypoglycaemia, a weight reduction and a reduction in arterial blood pressure. The efficacy of empagliflozin on HbA1c reduction increases according to the level of hyper¬glycaemia but decreases in patients with renal insufficiency...
October 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28381805/investigation-of-biodistribution-and-speciation-changes-of-orally-administered-dual-radiolabeled-complex-bis-5-chloro-7-131-i-iodo-8-quinolinolato-65-zn-zinc
#20
Masayuki Munekane, Masashi Ueda, Shinji Motomura, Shinichiro Kamino, Hiromitsu Haba, Yutaka Yoshikawa, Hiroyuki Yasui, Shuichi Enomoto
Many zinc (Zn) complexes have been developed as promising oral antidiabetic agents. In vitro assays using adipocytes have demonstrated that the coordination structures of Zn complexes affect the uptake of Zn into cells and have insulinomimetic activities, for which moderate stability of Zn complexes is vital. The complexation of Zn plays a major role improving its bioavailability. However, investigation of the speciation changes of Zn complexes after oral administration is lacking. A dual radiolabeling approach was applied in order to investigate the speciation of bis(5-chloro-7-iodo-8-quinolinolato)zinc complex [Zn(Cq)2], which exhibits the antidiabetic activity in diabetic mice...
2017: Biological & Pharmaceutical Bulletin
keyword
keyword
69589
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"